Anemoside A3-methyl 6-aminohexanoate
Based on 1 Customer Validation
Anemoside A3-methyl 6-aminohexanoate is an orally effective pyruvate carboxylase (PC) inhibitor with a Kd value of 10.1 μM against human PC. Anemoside A3-methyl 6-aminohexanoate exerts its function through the PC/NF-κB/NLRP3 inflammasome axis. Anemoside A3-methyl 6-aminohexanoate significantly alleviates symptoms of DSS (HY-116282C)-induced colitis in mice. Anemoside A3-methyl 6-aminohexanoate can be used in colitis-related research.
For research use only. We do not sell to patients.
- Purity : 98.62%
- CAS No.: 2919975-48-5
- Formula: C48H79NO13
- Molecular Weight:878.14
-
Storage:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Biological Activity
Description
IC50 & Target
[1]|
NF-κB |
IL-6 |
IL-1β |
NLRP3 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| THP-1 | IC50 |
>=80 μM
Compound: A3-6
|
Cytotoxicity against human THP-1 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK8 assay
Cytotoxicity against human THP-1 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK8 assay
|
[PMID: 38687956] |
In Vitro
Anemoside A3-methyl 6-aminohexanoate (Compound A3-6) (0-10 μM; 0-25 h) potently inhibits PC enzyme activity in THP-1-derived macrophages with an IC50 of 0.058 μM, reduces LPS (HY-D1056)-induced proinflammatory cytokine secretion, and regulates pyruvate metabolism in a concentration-dependent manner[1].
Anemoside A3-methyl 6-aminohexanoate (1-10 μM; 0-13.5 h) dose-dependently inhibits NF-κB pathway activation and NLRP3 inflammasome activation in THP-1-derived macrophages[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:THP-1-derived macrophages
-
Concentration:1, 10 μM (NF-κB pathway measurement); 1, 10 μM (NLRP3 inflammasome measurement)
-
Incubation Time:1 h prior to 6 h LPS stimulation (NF-κB pathway measurement); 1 h prior to 12 h LPS + 0.5 h ATP stimulation (NLRP3 inflammasome measurement)
-
Result:Inhibited LPS-induced increases in p-p65 and p-IκBα protein levels in a concentration-dependent manner.
Significantly reduced LPS + ATP-induced NLRP3, Pro-IL-1β, P20, and IL-1β protein levels.
-
Cell Line:Differentiated THP-1 cells treated LPS
-
Concentration:0.1, 1, 10 μM
-
Incubation Time:1 h prior to 24 h LPS stimulation
-
Result:Significantly decreased TNF-α
and IL-6 secretion in a concentration-dependent manner.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR mice (male, 20-25 g, DSS-induced ulcerative colitis)[1]
-
Dosage:15 mg/kg; 30 mg/kg; 60 mg/kg
-
Administration:i.g.; daily; 8 days
-
Result:Reduced DSS-induced body weight loss.
Dose-dependently decreased elevated disease activity index (DAI) scores.
Dose-dependently prevented colon shortening.
Reduced splenomegaly (lowered spleen index) in a dose-dependent manner.
Reduced colonic levels of the pro-inflammatory cytokine IL-6 in a concentration-dependent manner.
Decreased colon tissue pyruvate carboxylase (PC) activity at 60 mg/kg.
Increased colonic pyruvate levels at 60 mg/kg.
Inhibited DSS-induced IκBα degradation and P65 phosphorylation in mouse colon tissues.
Chemical Information
-
CAS No. 2919975-48-5
-
Appearance Solid
-
Molecular Weight 878.14
-
Formula C48H79NO13
-
Color White to off-white
-
SMILES
C=C(C)[C@@H]1CC[C@]2(C(NCCCCCC(OC)=O)=O)CC[C@@]3(C)[C@]4(C)CC[C@@]5([H])[C@](C)(CO)[C@@H](O[C@@H]6OC[C@H](O)[C@H](O)[C@H]6O[C@@H]7O[C@@H](C)[C@H](O)[C@@H](O)[C@H]7O)CC[C@]5(C)[C@@]4([H])CC[C@]3([H])[C@]21[H]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Solvent & Solubility
In Vitro:
DMSO : ≥ 100 mg/mL (113.88 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.1388 mL | 5.6939 mL | 11.3877 mL | 28.4693 mL |
| 5 mM | 0.2278 mL | 1.1388 mL | 2.2775 mL | 5.6939 mL | |
| 10 mM | 0.1139 mL | 0.5694 mL | 1.1388 mL | 2.8469 mL | |
| 15 mM | 0.0759 mL | 0.3796 mL | 0.7592 mL | 1.8980 mL | |
| 20 mM | 0.0569 mL | 0.2847 mL | 0.5694 mL | 1.4235 mL | |
| 25 mM | 0.0456 mL | 0.2278 mL | 0.4555 mL | 1.1388 mL | |
| 30 mM | 0.0380 mL | 0.1898 mL | 0.3796 mL | 0.9490 mL | |
| 40 mM | 0.0285 mL | 0.1423 mL | 0.2847 mL | 0.7117 mL | |
| 50 mM | 0.0228 mL | 0.1139 mL | 0.2278 mL | 0.5694 mL | |
| 60 mM | 0.0190 mL | 0.0949 mL | 0.1898 mL | 0.4745 mL | |
| 80 mM | 0.0142 mL | 0.0712 mL | 0.1423 mL | 0.3559 mL | |
| 100 mM | 0.0114 mL | 0.0569 mL | 0.1139 mL | 0.2847 mL |